List of Excipients in Branded Drug TIOPRONIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	HYDROXYPROPYL CELLULOSE
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	HYPROMELLOSE
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	LACTOSE MONOHYDRATE
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	MAGNESIUM STEARATE
BioComp Pharma Inc	TIOPRONIN	tiopronin	44523-054	METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER

Generic Drugs Containing TIOPRONIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	AMMONIA
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	ETHYLCELLULOSE
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	FERROSOFERRIC OXIDE
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	GLYCERYL MONOCAPRYLOCAPRATE
Teva Pharmaceuticals USA Inc	tiopronin	0093-7909	GLYCERYL MONOSTEARATE

What are the Most Frequently-Used Excipients in TIOPRONIN?

# Of NDCs	Excipient
1	ALCOHOL
3	AMMONIA
1	ANHYDROUS LACTOSE
1	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
1	DIMETHICONE

Excipient Strategy and Commercial Opportunities for Tiopronin

Last updated: February 26, 2026

What is Tiopronin?

Tiopronin, marketed under the brand name Thiola, is a thiol compound used primarily for the treatment of cystinuria, a hereditary disorder characterized by cystine stone formation in the kidneys. Approved by the FDA in 2002, it functions by decreasing cystine levels in urine to prevent stone formation (FDA, 2002).

Excipient Strategy for Tiopronin

Current Formulation Components

Tiopronin is supplied as oral capsules. The formulation typically contains:

• Active ingredient: Tiopronin
• Excipients: Gelatin capsule shell, microcrystalline cellulose, magnesium stearate, and titanium dioxide as a pigment.

The capsule shell's composition influences stability, bioavailability, and shelf life. Microcrystalline cellulose acts as a filler, while magnesium stearate functions as a lubricant during manufacturing.

Optimization of Excipient Selection

Enhancing the excipient profile focus on:

• Bioavailability: Using excipients that facilitate absorption (e.g., surfactants, absorption enhancers) could improve gastrointestinal uptake, especially if new formulations aim for alternative delivery routes.
• Stability: Incorporating antioxidants like ascorbyl palmitate can prevent oxidation of the thiol group, extending shelf life.
• Patient tolerability: Choosing non-hypoallergenic capsules and excipients free from gluten or lactose can improve acceptance, especially in targeted populations.

Innovative Approaches

• Liquid formulations: Transitioning from capsules to solutions or suspensions could broaden administration options and improve compliance.
• Extended-release formulations: Using matrix systems or coating techniques to control release, maintaining steady plasma levels and reducing dosing frequency.
• Alternative excipients: Replacement of gelatin capsules with plant-based alternatives can improve acceptance among vegetarians and certain demographic groups.

Regulatory Considerations

Changing excipients or formulation types requires pre-approval by regulatory authorities. Demonstrating stability, bioequivalence (for reformulated versions), and safety profiles is paramount.

Commercial Opportunities for Tiopronin

Market Overview

The specific niche for Tiopronin centers on cystinuria management. The global cystinuria market is estimated at approximately USD 60 million in 2023, with growth driven by increased diagnosis and awareness (MarketLine, 2023).

Competition Landscape

• Existing therapies: D-penicillamine, which is older and associated with toxicity, remains a competitor.
• Pipeline drugs: Newer cystine-lowering agents, such as tiopronin analogs and other thiol compounds, are in developmental stages.

Strategic Opportunities

• Formulation diversification: Developing non-capsule formulations (liquids, extended-release) can capture a broader patient base, including pediatric and elderly populations.
• Patent extensions: Reformulation with novel excipients or delivery systems can foster patent life extension.
• Partnerships: Collaborations with specialty pharmacies and compounding providers open avenues for customized formulations.

Regulatory and Market Entry Strategies

• Fast-track pathways: Orphan drug designation for cystinuria can expedite approval processes.
• Pricing strategies: Positioning as a low-cost alternative to D-penicillamine with improved safety profiles can increase market penetration.

Challenges

• Limited market size: Niche indication limits revenue potential.
• Regulatory hurdles: Reformulations necessitate comprehensive testing and approval, impacting time to market.
• Market awareness: Educating healthcare providers on benefits over alternatives is essential for uptake.

Key Takeaways

• Tiopronin formulations rely on excipients (gelatin, microcrystalline cellulose, magnesium stearate) critical for stability and delivery.
• Innovating excipients and formulation types (liquids, extended-release) presents significant commercial potential.
• Capitalizing on regulatory pathways and strategic positioning as a safer alternative to older therapies can open market opportunities.
• Market size remains limited but stable, emphasizing the importance of formulation differentiation and regulatory advantages.

FAQs

1. What excipients are critical in Tiopronin capsules?
Gelatin, microcrystalline cellulose, magnesium stearate, and titanium dioxide for pigmentation.

2. How can excipient optimization improve Tiopronin delivery?
Enhancing bioavailability, stability, and tolerability by selecting excipients that facilitate absorption, prevent oxidation, and suit patient preferences.

3. What formulation approaches could expand Tiopronin's market?
Liquid suspensions, extended-release capsules, and plant-based capsules could increase patient compliance and access.

4. Are there regulatory incentives for reformulating Tiopronin?
Yes, orphan drug designations and potential patent extensions can provide regulatory and commercial advantages.

5. What are the main barriers to market expansion?
Limited market size, regulatory approval costs for new formulations, and competition from existing drugs.

References

1. U.S. Food and Drug Administration (FDA). (2002). Tiopronin (Thiola) Approval. Retrieved from [FDA website].
2. MarketLine. (2023). Global cystinuria market report. MarketLine Insights.